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Inhibition of heme oxygenase-1 (HO-1, encoded by 
HMOX1), a cytoprotective, anti-apoptotic and anti-inflam-
matory enzyme, may serve as a valuable therapy in vari-
ous pathophysiological processes, including tumorigene-
sis. We compared the effect of chemical inhibitors – met-
alloporphyrins, with genetic tools – shRNA and CRISPR/
Cas9 systems, to knock-down (KD)/knock-out (KO) HO-1 
expression/activity. 293T cells were incubated with met-
alloporphyrins, tin and zinc protoporphyrins (SnPPIX 
and ZnPPIX, respectively) or were either transduced with 
lentiviral vectors encoding different shRNA sequences 
against HO-1 or were modified by CRISPR/Cas9 system 
targeting HMOX1. Metalloporphyrins decreased HO ac-
tivity but concomitantly strongly induced HO-1 mRNA 
and protein in 293T cells. On the other hand, only slight 
basal HO-1 inhibition in shRNA KD 293T cell lines was 
confirmed on mRNA and protein level with no signifi-
cant effect on enzyme activity. Nevertheless, silencing 
effect was much stronger when CRISPR/Cas9-mediated 
knock-out was performed. Most of the clones harbor-
ing mutations within HMOX1 locus did not express HO-1 
protein and failed to increase bilirubin concentration 
after hemin stimulation. Furthermore, CRISPR/Cas9-me-
diated HO-1 depletion decreased 293T viability, growth, 
clonogenic potential and increased sensitivity to H2O2 
treatment. In summary, we have shown that not all tech-
nologies can be used for inhibition of HO activity in vitro 
with the same efficiency. In our hands, the most potent 
and comprehensible results can be obtained using ge-
netic tools, especially CRISPR/Cas9 approach.
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INTRODUCTION
Heme oxygenase-1 (HO-1, encoded by HMOX1), 
first characterized in 1968 (Tenhunen et al., 1968), is an 
enzyme responsible for the degradation of pro-oxidant 
heme, which leads to the release of carbon monoxide 
(CO), ferrous ion (Fe2+), and biliverdin. Besides its an-
tioxidant function (Stocker, 1990), HO-1 is considered 
as a regulator of cellular homeostasis, a modulator of 
inflammatory response and angiogenesis. Unfortunately, 
all of potentially beneficial properties of HO-1 can con-
tribute to pathophysiological processes, such as diabetes, 
hypertension or tumorigenesis (Deshane et al., 2005). 
Indeed, a growing body of evidence suggests an impor-
tant role of HO-1 in various types of cancer (Loboda et 
al., 2015). Therefore, inhibition of HO-1 can potentially 
serve as an anticancer therapy.
Several approaches for HO-1 silencing are used in 
experimental settings; however, due to the off-target ef-
fects, their experimental and possibly therapeutic applica-
tion, at least in some cases, is strongly limited. Pharma-
cological agents, like commonly used metalloporphyrins 
might, apart from targeting HO, modulate the activity 
of nitric oxide synthase (NOS), soluble guanylate cyclase 
(sGC) and cytochrome P450 (Loboda et al., 2015). The 
most commonly used genetic tools for specific HO-1 
inhibition are small interfering RNA (siRNA) or short 
hairpin RNA (shRNA) that bind to a complementary se-
quence in targeted mRNA and predominantly induce its 
cleavage (Rao et al., 2009). In vitro, decreased levels of 
HO-1 achieved by RNAi resulted in increase in apopto-
sis of lung cancer cells (Kim et al., 2008) and augmented 
sensitivity to anticancer therapy in pancreatic cancer cells 
(Berberat et al., 2005). Moreover, siRNA-mediated HO-1 
downregulation led to diminished growth of tumours in 
vivo in the orthotopic model of hepatocellular carcinoma 
(Sass et al., 2008). Although the RNAi approach is very 
useful in experimental settings, its potential therapeutic 
application remains limited. Major obstacles include inef-
ficient delivery of the genetic material, variable knock-
down efficiencies, poor stability due to the degradation 
by RNases present in body fluids and, in some cases, the 
possible induction of immune response (Reynolds et al., 
2006; Aagaard & Rossi, 2007). Additionally, siRNA and 
shRNA sequences can exhibit off-target effects by inhib-
iting undesired genes (Qiu et al., 2005).
CRISPR/Cas9 system was adopted from bacterial im-
mune defense system against foreign DNA and modi-
fied for the purpose of genome engineering. In this ap-
proach, Cas9 promotes genome editing by stimulating a 
double-strand breaks (DSB) formation at a target genom-
ic locus. DSB can be repaired either by non-homologous 
end joining (NHEJ) or homology-directed repair (HDR). 
DSB repair by NHEJ often results in small insertions or 
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deletions (indels) and, if DSB occurred within coding re-
gion of a gene, indel mutations can change the mRNA 
reading frame leading to the introduction of prema-
ture stop codon and, as a consequence, gene knock-out 
(Hendriks et al., 2016). CRISPR/Cas9 has provided an 
easy and efficient genome editing tool in cultured hu-
man cells (Cho et al., 2013; Cong et al., 2013; Mali et al., 
2013), Drosophila (Gratz et al., 2013), zebrafish (Hwang et 
al., 2013), or plants (Xie & Yang 2013) and currently is 
a widely used approach for generation of knock-out ani-
mal models, due to its simplicity, efficiency, and specific-
ity (Housden et al., 2017). As a new and still developing 
method, its advantages, drawbacks, and applications still 
need to be determined.
The aim of the present study was to compare the ef-
fectiveness of both pharmacological and genetic inhibi-
tion of HO-1 in a model cell line, human embryonic 
kidney 293T cells, and to identify the possible benefits 
and limitations of the used methods.
MATERIALS AND METHODS
Cell culture. Human embryonic kidney 293T cells 
(kindly obtained from dr Maciej Wiznerowicz from 
Wielkopolskie Centrum Onkologii, Poznan, Polska) were 
cultured under standard conditions (37°C, 5% CO2) in 
high glucose (4.5 g/L) Dulbecco’s Modified Eagle’s me-
dium – DMEM (Lonza, Basel, Switzerland), supplement-
ed with 10% fetal bovine serum (FBS, Biowest, Nuaillé, 
France/EURx, Gdansk, Polska) and antibiotics: 100 U/
mL penicillin and 100 μg/mL streptomycin (Lonza, Ba-
sel, Switzerland).
Cells stimulation. Cells growing in 96-well plates 
(3 000 or 5 000/well), 48-well plates (50 000/well), 24-
well plates (200 000/well), 6-well plates (650 000/well) 
or 10 cm dishes (2.0 × 106/dish) were stimulated for 
cell viability or proliferation, immunofluorescence, RNA 
isolation, protein analysis and HO activity, respectively. 
SnPPIX and ZnPPIX (Frontier Scientific, Logan, UT, 
USA, dissolved in DMSO) were used at 0.5–25 µM for 
6 h or 24  h, whereas hemin (Calbiochem, San Diego, 
CA, USA), was dissolved in phosphate buffer with 10 
mM NaOH and added at 50 µM for 6 h or at 10 µM 
for 24 h. Hydrogen peroxide (H2O2) at 0.05–0.5 mM 
concentration was used for 24 h stimulation. The control 
cells received the appropriate solvent.
Production of lentiviral vectors encoding shRNA 
sequences against HMOX1. Four 29-mer shRNA con-
structs (shHO-1 A-D) against human HMOX1 and one 
29-mer non-targeting shRNA (scrambled shRNA) in 
pGFP-C-shLenti vectors were purchased from OriGene 
(Rockville, MD, USA). 293T cells were transfected with 
plasmids of interest and two helper plasmids: pMD2.G 
and psPAX2as described previously (Szulc et al., 2006) 
using polyethylenimine – PEI (Polysciences, Inc., War-
rington, PA, USA) as a transfection reagent. The plas-
mids were a gift from Didier Trono (Addgene plasmids 
#12259 [pMD2.G] and #12260 [psPAX2]). Transfec-
tion efficiency was monitored under fluorescent micro-
scope by the assessment of GFP positive cells. 48 h 
and 72 h after transfection, media containing lentiviral 
vectors were collected and pooled. The vector titers were 
determined by transduction of 293T cells with lentiviral 
vectors and subsequent analysis of the fraction of GFP 
positive cells using flow cytometer (BD Fortessa).
Stable transduction with lentiviral vectors. 293T 
cells were transduced with lentiviral vectors encoding 
either scrambled shRNA (control cells) or one of four 
shRNAs against HMOX1 (shHO-1 A-D) in the presence 
of 5 μg/mL polybrene (Sigma-Aldrich, St. Louis, MO, 
USA). Multiplicity of infection (MOI) of 20 was used 
and after 72 h the GFP positive cells were sorted using 
MoFlo XDP cell sorter (Beckman-Coulter).
Knock-out 293T generation. For the generation of 
HO-1 deficient 293T cells pX330-Pac-Cer plasmid that 
encode sgRNA targeting human HMOX1 locus or an 
empty vector (control cells) has been used as described 
previously (Czarnek & Bereta, 2017). Cell clones con-
taining mutations in HMOX1 locus (assessed by CELI 
mismatch detection assay) were used for further analyses.
Colony formation assay. 1 000 cells were seed-
ed on 12-well plates and grown for 7 days. Afterwards 
cells were fixed with cold (–20°C), 100% methanol for 
20 minutes on ice and stained with 0.05% (w/v) crys-
tal violet (BioShop, Burlington, Ontario, Canada) in 20% 
methanol for 20 minutes at room temperature. Crystal 
violet was then completely removed and pictures of the 
plates were taken using Fusion FX5 XT camera (Vilber).
MTT viability assay. To assess viability of cells, 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide) (Sigma-Aldrich, St. Louis, MO, USA) assay 
was used. After 24 h stimulation with H2O2, cells were 
incubated with 1 mg/mL MTT in medium for 2 h at 
37°C. Then, formazan crystals were dissolved in 100 
µL/well of lysis buffer consisting of 0.6% (v/v) acetic 
acid and 10% (w/v) SDS in DMSO and absorbance at 
570 nm with the reference value of 690 nm was mea-
sured using Infinite M200 microplate reader (Tecan).
Cell proliferation. To determine cell growth over the 
time, CyQUANT Cell Proliferation Assay (Thermo Fish-
er Scientific, Waltham MA, USA) was performed accord-
ing to the manufacturer’s instructions.
Heme oxygenase activity assay. Heme oxygenase 
activity was determined in cell lysates according to the 
method previously described (Foresti et al., 1997) with 
slight modification regarding the source of biliverdin 
reductase (BVR). BVR was produced in BL21(DE3) 
RIL competent bacteria after transformation using 
pET24a+:rBVR plasmid with kanamycin resistance. Bac-
teria were cultured in LB with 30 µg/mL kanamycin at 
37°C until optical density (OD600) reached values be-
tween 0.6–0.8. Induction of rBVR expression was carried 
out by addition of 0.1 mM Isopropyl β-d-1-thiogalacto-
pyranoside (IPTG) for 5 h at 30°C. Bacteria pellet was 
dissolved in buffer containing 20 mM imidazol, 300 mM 
NaCl and 20 mM Tris/HCl, pH 7.4 in ratio: 1 g of the 
bacteria to 5 mL of the buffer and lysed by sonification. 
After centrifugation (7500 rpm, 5 minutes), purification 
of the rBVR was performed by loading the supernatant 
on a column packed with Ni Sepharose HighPerfor-
mance resin. Elution of the rBVR was carried out by us-
ing buffer with 500 mM imidazol, 300 mM NaCl and 20 
mM Tris/HCl pH 7.4. After elution protein was dialyzed 
for 18 h at 4°C against 300 mM NaCl and 20 mM Tris/
HCl pH 7.4 buffer. Subsequently protein was condensed 
to about 10 mg/mL concentration, glycerol was add-
ed to final 50% concentration and rBVR was frozen at 
–20°C. 25 µg/ml BVR was used for HO activity assay.
In brief, after 6 h stimulation with 50 μM hemin cells 
were scraped in 100 mM phosphate buffer with 2 mM 
MgCl2. After three cycles of freeze (in liquid nitrogen) 
and thaw (at 37°C) cell lysate was added to a reaction 
mixture containing NADPH, glucose-6-phosphate, glu-
cose-6-phosphate dehydrogenase (Sigma-Aldrich, St. 
Louis, MO, USA), BVR and the substrate hemin. After 
1 h incubation of the above mixture in the dark at 37°C 
the reaction was terminated by the addition of chloro-
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form (POCH, Gliwice, Polska). Followed vigorous vor-
texing (extraction) and centrifugation (phase separation), 
the concentration of extracted bilirubin was measured by 
the difference in absorbance between 464 nm and 530 
nm (ε = 40 mM–1 cm–1) and calculated as picomole of bil-
irubin formed per milligram protein per hour.
Quantitative RT-PCR. RNA was isolated from cul-
tured cells using Fenozol (A&A Biotechnology, Gdynia, 
Polska) with modified Chomczynski and Sacchi method 
(Chomczynski & Sacchi, 1987). RNA concentration and 
purity were determined using NanoDrop 1000 (Thermo 
Fisher Scientific, Waltham MA, USA). Reverse transcrip-
tion was performed with SuperScript polymerase (In-
vitrogen, Carlsbad, CA, USA) according to instructions 
supplied by the manufacturer. Obtained cDNA was 
used as a template for quantitative real-time PCR with 
SybrGreen Mix (Sigma-Aldrich, St. Louis, MO, USA) 
and specific primers (HMOX1 F:5’-TTCTTCACCTTC-
CCCAACATT-3’, R: 5’-CAGCTCCTGCAACTCCT-
CAAA-3’; HMOX2: F: 5’-GATCGTGGAGGAGGC-
CAACA-3’, R: 5’-TAGAAAGGGCATTTACGCAT-3’; 
EEF-2 F: 5’-GAGATCCAGTGTCCAGAGCAG-3’; 
R:5’-CTCGTTGACGGGCAGATAGG-3’). EEF2 (en-
coding eukaryotic translation elongation factor 2, EF-2) 
was used for gene expression normalization. The reac-
tion was performed using a StepOnePlus TM Real-time 
PCR Systems (Applied Biosystems).
Western blot. Cultured cells were lysed with RIPA 
buffer and 25–30 µg of protein lysates were loaded on 
12% SDS-PAGE gel followed by electrophoresis and 
wet transfer of proteins to nitrocellulose membrane 
(30 V/overnight). Membranes were blocked with 5% 
non-fat milk in TBS (Tris-buffered saline, BioShop, Bur-
lington, Ontario, Canada) + 0.1% (v/v) Tween-20 (Bio-
Shop, Burlington, Ontario, Canada) for 1.5 h at room 
temperature. Primary antibodies diluted in blocking solu-
tion: rabbit anti-HO-1 (ADI-SPA-894, Enzo Life Sci-
ence, Farmingdale, NY, USA, 1:500), mouse anti-α-tu-
bulin (CP06, Calbiochem, San Diego, CA, USA, 1:1 000) 
were used for overnight incubation at 4°C. Next day, 
membranes were washed and incubated with secondary 
antibodies conjugated with HRP: goat anti-mouse (BD 
Pharmingen, San Diego, CA, USA, 1:10 000) and goat 
anti-rabbit (Cell Signaling Technology, Danvers, MA, 
USA, 1:5 000) for 1 h at room temperature. After series 
of washings, luminescent substrate for HRP activity (Im-
mobilon Chemiluminescent HRP Substrate, Merck Milli-
pore, Billerica, MA, USA) was added for 10 minutes and 
membranes were manually developed on X-ray film.
Immunofluorescence. Cells were fixed in 4% para-
formaldehyde for 10 minutes, permeabilized with 0.05% 
(v/v) TritonX-100 for 5 minutes and incubated for 30 
minutes in 0.25% (w/v) glycine in PBS. Afterwards, cells 
were blocked in 10% (v/v) goat serum (Sigma-Aldrich, 
St. Louis, MO, USA) in PBS for 1 h at room tempera-
ture followed by incubation (overnight at 4°C) with pri-
mary antibody rabbit anti-HO-1 (ADI-SPA-894, Enzo 
Life Science, Farmingdale, NY, USA) diluted 1:200 in 
1% (v/v) goat serum in PBS. Next day, cells were in-
cubated with secondary antibody goat anti-rabbit Alexa 
Fluor 488 or 568 (Thermo Fisher Scientific, Waltham 
MA, USA) diluted 1:500 in 1% (v/v) goat serum to-
gether with 10 µg/mL Hoechst (Sigma-Aldrich, St. Lou-
is, MO, USA) for 2 h at room temperature, visualized 
Figure 1. Inhibition of HO activity using SnPPIX and ZnPPIX affects HMOX1 but not HMOX2 mRNA level in 293T cell line. 
HO activity after 6 h stimulation with SnPPIX/ZnPPIX shown as the percentage of control (mean ± SD) (A). HMOX1 and HMOX2 mRNA 
after 6 h (B, D, respectively) and after 24 h (C, E, respectively) stimulation with 1-25 µM SnPPIX/ZnPPIX calculated as relative fold change 
vs. control (mean ± S.D.).
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under fluorescent microscope and analyzed using ImageJ 
program.
Statistical analysis. All experiments were performed 
in duplicates or triplicates and were repeated two or 
three times. Results are presented as a mean ± S.D. 
(standard deviation). Statistical analysis was performed in 
GraphPad Prism Software using Student’s t-test or one-
way ANOVA. Results were considered statistically sig-
nificant at p < 0.05
RESULTS
Protoporphyrins inhibit HO activity but upregulate 
HO-1 mRNA and protein
Protoporphyrins, SnPPIX and ZnPPIX are widely 
used inhibitors of HO activity. In our hands, 6 h stim-
ulation with either inhibitor led to potent decrease in 
bilirubin production by 293T cells, with much stronger 
effect of ZnPPIX (Fig. 1A). Nonetheless, already 6 h 
stimulation with ZnPPIX resulted in significant induc-
tion of HMOX1 mRNA (Fig. 1B). After longer time 
(24 h), the stimulatory effect of SnPPIX on HMOX1 
expression was also visible (Fig. 1C), but was not as 
pronounced as after ZnPPIX treatment which was 
even further increased in comparison to 6 h stimulation 
(Fig. 1C). Noteworthy, 6 h (Fig. 1D) and 24 h (Fig. 1E) 
treatment with protoporphyrins had no significant effect 
on the mRNA expression of constitutive form of HO, 
HMOX2. The induction of HO-1 protein by protopor-
phyrins was confirmed by Western blot (Fig. 2A) and 
immunofluorescent staining (Fig. 2B).
shHO-1 fail to abolish HO activity induction upon 
hemin treatment
293T cells were transduced with lentiviral vectors en-
coding shRNA against HO-1 (shHO-1 A-D) and scram-
bled shRNA (further referred to as control cells) and 
the efficiency of the transduction was monitored using 
fluorescent microscope and flow cytometer (Fig. 3A). 
After sorting GFP+ cells, HO-1 expression was evalu-
ated. We observed a decrease in basal HMOX1 mRNA 
in cells transduced with three out of four tested shR-
NAs (sequences B-D, Fig. 3B); however, 6 h stimulation 
with hemin, HO-1 inducer, caused potent induction of 
HMOX1 in cells transduced either with scrambled shR-
NA or all shHO-1 (Fig. 3C). HMOX2 mRNA was af-
fected neither by shHO-1 transduction (Fig. 3D) nor by 
hemin treatment (Fig. 3E). Moreover, basal HO-1 pro-
tein level was decreased in cells transduced with shHO-1 
B-D sequences (Fig. 4A, B). Hemin-induced HO-1 up-
regulation was observed in shHO-1 KD cells but it was 
not as potent as in control cells, as shown by immuno-
fluorescent staining (Fig. 4A) and Western blot (Fig. 4B). 
Finally, HO activity was not significantly changed in ba-
sal conditions (Fig. 4C). In accordance with the mRNA 
and protein results after hemin stimulation, all shHO-
1 cells showed increase in HO activity similar to cells 
transduced with scrambled shRNA (Fig. 4D).
CRISPR/Cas9-mediated gene editing of HMOX1 locus 
results in HO-1 deficiency
In order to obtain HO-1 knock-out cells, 293T cells 
were transiently transfected with vectors coding for 
two distinct sgRNAs that target second exon of hu-
man HMOX1 locus (Fig. 5A). We chose second exon 
because it encodes histidine 25, which is prerequisite 
for HO-1 catalytic activity and plasmids may be used 
in future to create mutant clones with catalytically inac-
tive HO-1 instead of HMOX1 knock-out clones. Upon 
transfection, the cells were selected with puromycin 
for 24 h and seeded on 96-well plate to obtain single 
cell-derived clones. After further amplification of cells, 
DNA was isolated and CELI mismatch detection assay 
was performed to evaluate the presence of mutations 
in HMOX1 amongst the obtained clones (Fig. 5B). Of 
Figure 2. Pharmacological inhibitors of HO activity potently increase HO-1 protein level.
Western blot analysis of HO-1 protein after 24 h stimulation with inhibitors (0.05–25 µM) and 10 µM hemin (H) (A). Immunofluorescent 
detection of HO-1 protein (green) after 24 h stimulation with protoporphyrins (0.05–25 µM), counterstained with Hoechst (B). *p<0.05 vs. 
control.
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note, among 31 tested clones, 18 harbored mutations in 
HMOX1 locus (Fig. 5C).
Due to CRISPR/Cas9-mediated introduction of pre-
mature stop codons and subsequent degradation of de-
fective transcripts in nonsense-mediated decay process, 
we observed diminished level of HMOX1 transcript 
in several clones harboring mutations in HMOX1 lo-
cus. The most pronounced difference was detected in 
clones 4.4, 4.8 and to a lesser extent in clones 4.14 and 
4.20 (Fig. 6A). Hemin-induced HMOX1 expression was 
Figure 3. shRNA-mediated HMOX1 silencing fails to abolish HMOX1 induction after hemin treatment. 
Representative pictures of cells transduced with lentiviral vectors encoding shRNA against HMOX1 (100x) and percentage of GFP+ cells 
(A). HMOX1 and HMOX2 (B, D, respectively) expression after transduction with shHO-1 A-D and scrambled shRNA, presented as relative 
fold change vs. control (mean ± S.D.).
Figure 4. shRNA-mediated silencing of HMOX1 partially decreases basal and hemin-induced protein level, with no effect on HO-1 
activity level. 
HO-1 protein level assessed in basal and hemin-induced (6 h stimulation) conditions by immunofluorescent staining (red) counterstained 
with Hoechst (A) and by Western blot (B). HO activity under basal (C) and hemin-stimulated (6 h) conditions (D). HO activity under basal 
conditions is shown as percentage of control and at hemin-induced conditions as percentage of basal conditions for appropriate cell line 
(mean ± S.D.). * p<0.05 vs. control.
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blunted in several clones, in comparison to hemin-stim-
ulated control cells (Fig. 6B). Basal HMOX2 mRNA 
level was not affected in majority of clones (Fig. 6C) 
whereas some inhibition was detected in hemin-stim-
ulated cells (Fig. 6D). Both basal and hemin-induced 
HO-1 protein level was potently decreased mostly in 
clones 4.4, 4.8, 4.10 and 4.14 (Fig. 7A, 7B). Most prob-
ably, those clones harbor frameshift mutation in all 
HMOX1 loci. HO activity, which is a combined activ-
ity of HO-1 and HO-2, was not changed in basal con-
ditions (Fig. 7C) (except for the clone 4.8), but most 
importantly, lack of response to hemin stimulation (as 
the result of blocked HO-1 activity) in all clones was 
observed (Fig. 7D).
CRISPR/Cas9-mediated HO-1 depletion affects 293T cells 
viability and growth
HO-1 depletion in 293T cells caused slight, but sig-
nificant drop in the cell growth in clones 4.8, 4.10, 
4.14, as checked by CyQUANT analysis (Fig. 8A). 
Furthermore, tested clones (4.8 and 4.10) exhibited 
decreased viability in basal conditions and significant-
ly higher susceptibility to 0.5 mM H2O2 stimulation 
in comparison to control cells (Fig. 8B). Additionally, 
clonogenic potential of 293T cell line was significantly 
impaired by HO-1 depletion in comparison to control 
cells (Fig. 8C).
DISCUSSION
Due to the growing body of evidence suggesting the 
relevance of HO-1 inhibition as a possible therapeu-
tic strategy, especially in tumour biology, we decided to 
provide a comprehensive comparison of pharmacologi-
cal and genetic approaches of HO-1 silencing in a model 
cell line, human embryonic kidney cells 293T.
Experimental and medical application of metallopor-
phyrins is limited mostly due to their poor specificity, 
low bioavailability, and the modulation of pathways not 
directly related to HO (Grundemar & Ny, 1997; Schulz 
et al., 2012). Accordingly, ZnPPIX has been demon-
strated to regulate the indoleamine-2,3-dioxygenases 
activity (Metz et al., 2010), cyclin D1 expression (Rah-
man et al., 2009), and Wnt/β-catenin pathway (Wang et 
al., 2013). We have previously shown that SnPPIX and 
ZnPPIX may oppositely regulate the activity of induc-
ible nitric oxide synthase (iNOS), as SnPPIX augmented 
whereas ZnPPIX decreased production of NO in vascu-
lar smooth muscle cells as well as in macrophages and 
those effects were HO-1 independent (Jozkowicz & Du-
lak 2003).
As reported in the present study, both SnPPIX and 
ZnPPIX almost completely abolished total HO activity, 
emphasizing their unspecificity towards HO isoforms. 
At the same time, we observed strong upregulation of 
HO-1 both at mRNA and protein levels. This effect was 
Figure 5. Efficient CRISPR/Cas9-mediated introduction of mutations in HMOX1 in 293T cell line. 
Schematic representation of human HMOX1 locus showing the location of HMOX1-targeting sgRNAs (grey lines; PAM sequences are 
shown in black). Black lines represent introns and rectangles represent exons. DNA sequence of fragment of exon 2 is shown below; 
sequence of the protein translated from this fragment is given immediately above the nucleotide sequence; H25 is shown in bold (A). 
Designed sgRNAs were further utilized to generate HO-1 knockout clones of 293T cells according to general scheme of CRISPR/Cas9-
mediated gene editing (B). Efficient introduction of mutations in HMOX1 in derived clones was confirmed using CELI mismatch detection 
assay (C). The results are presented as percentage of clones with detected mutations upon utilization of two sgRNAs sequences.
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also reported in other cell types and tissues (Loboda et 
al., 2015). It has been proposed that such a dual action 
might be related to the fact that metalloporphyrins, act-
ing as the analogues of heme, could remove transcrip-
tional Bach1 repressor, induce HMOX1 transcription 
through Nrf2 activation, and simultaneously inhibit 
its activity by binding to the catalytic pocket of HO-1 
(Ogawa et al., 2001). Additionally, it was reported that 
Figure 6. Genetic inhibition of HMOX1 in 293T using CRISPR/Cas9 system significantly decreases HMOX1 but not HMOX2 mRNA level 
both under basal and hemin-induced conditions.
HMOX1 and HMOX2 expression in control clone and in clones after CRISPR/Cas9-mediated HO-1 excision in basal (A, C, respectively) and 
in hemin-induced conditions (B, D, respectively). Basal level was calculated as relative fold change vs. control whereas hemin-induced 
HMOX1 expression is shown as relative fold change vs. basal conditions for each clone (mean ± S.D.).
Figure 7. Genetic inhibition of HMOX1 in 293T using CRISPR/Cas9 system leads to potent decrease in HO-1 protein level both under 
basal and hemin-induced conditions as well as on activity level after treatment with hemin. 
Inhibition of HO-1 protein level by CRISPR/Cas9-mediated HO-1 excision checked by immunofluorescent staining (A) and Western Blot 
(B) both under basal conditions and after 6 h stimulation with 50 μM hemin. HO activity in basal conditions (C) and after 6 h stimulation 
with 50 μM hemin (D). HO activity at basal conditions shown as percentage of control and hemin treatment as percentage of basal con-
ditions for appropriate clone (mean ± S.D.).*p<0.05 vs. control; $p<0.05 vs. control cells treated with hemin.
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ZnPPIX mediates binding of early growth response-1 
(Egr-1) to the promoter of HO-1, which then induces its 
expression (Yang et al., 2001). Summarizing, due to HO-
independent, unspecific effects, results obtained using 
metalloporphyrins should be analysed with caution and 
the involvement of the HO-1 pathway should be always 
confirmed by more specific methods.
Despite high transduction efficiency in 293T cells 
obtained in the shRNA approach, most of the tested 
shRNA sequences decreased HMOX1 mRNA level 
only to about 35% of that in control. This partial effect 
can be cell type-specific but also connected to some 
internal protective mechanism in cells. The increase in 
MOI of used vectors would be one option to augment 
the effectiveness; however, it might also lead to tox-
icity and off-target effects. Moreover, it appeared im-
portant to test few different shRNA sequences, since 
the efficacy of each of them can vary (Alaoui-Jamali et 
al., 2009). It was also clearly visible in our hands that 
shHO-1 sequence A only slightly diminished HMOX1 
expression with no changes on protein level. Fortu-
nately, none of tested sequences influenced HMOX2 
transcript, which suggests specificity regarding HO iso-
forms. This also explains the lack of the effect on basal 
HO activity, which probably reflects mostly the activ-
ity of HO-2, the isoform predominant in physiological 
conditions, rather than HO-1. Furthermore, significant 
induction of HMOX1 mRNA, protein, and activity in 
response to hemin stimulation was still visible and can 
be related to insufficient inhibition of newly transcribed 
HMOX1 mRNA by shRNA. The lack of possibility to 
inhibit the increase in HO activity in response to the 
stimuli is an important and major drawback of this ap-
proach as HO-1 is easily-inducible enzyme (Ferrandiz 
& Devesa 2008).
In the present study we have clearly shown the advan-
tage of CRISPR/Cas9 technology over shRNA method. 
Although we observed differences in efficiency of HO-1 
depletion between tested clones which can be related to 
natural variability between cells or some pitfalls of CRIS-
PR/Cas9 technology (Peng et al., 2016) and emphasize 
the need for careful selection of clones used for further 
studies, our data clearly demonstrate the usefulness of 
this method. It has to be stressed that despite the fact 
that HMOX1 transcript which is most probably mu-
tated, can be still present in cell clones transfected with 
CRISPR/Cas9 targeting HMOX1, the functionality of 
the protein is lost. HO-1 protein level in CRISPR/Cas9-
derived cell clones was diminished, both in basal and 
hemin-induced conditions and, what is most important, 
no increase in HO activity upon stimulation with potent 
inducer of HO-1, hemin, was observed. This reflects the 
necessity of validation of the obtained results not only at 
mRNA or protein levels, but essentially based on the bi-
ological functionality, which in our case is a real indica-
tor of the effectiveness of the CRISPR/Cas9 approach.
Importantly, the lack of HO-1 in 293T cells exerts 
serious biological consequences, including decreased clo-
nogenic potential and cell proliferation as well as dimin-
ished cell viability. Moreover, cells with HO-1 deficiency 
are more susceptible to H2O2 stimulation, which is con-
nected to the cytoprotective role of HO-1 against stress-
ful conditions. Therefore, HO-1 may be a good antican-
cer target. Indeed, a growing body of evidence suggests 
the emergent role of HO-1 in various types of cancer, 
including melanoma, renal cell carcinoma, pancreatic can-
Figure 8. The effect of HMOX1 inhibition by CRISPR/Cas9 system on viability, proliferation and clonogenic potential of 293T cell line. 
CyQUANT assay to estimate relative growth rate was performed after 4 days from seeding. The results are presented as percentage of 
control (mean ± S.D.) (A). MTT analysis on cells stimulated with H2O2 (0.05-0.5 mM) for 24h and calculated as percentage of control (mean 
± S.D.) (B). Clonogenic potential checked 7 days after seeding – representative pictures (C). *p<0.05 vs. control; $p<0.05 vs. control cells 
of each clone.
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cer, and many others. Elevated levels of HO-1 in cancer 
cells in comparison to cells from healthy tissues has been 
associated with different aspects of tumour biology, lead-
ing to progression of the disease (Loboda et al., 2015). 
Furthermore, expression of HO-1 can be induced upon 
anticancer treatment, which often results in decreased ef-
fectiveness. Nonetheless, the exact role of HO-1 in tu-
mour biology is multifaceted, since the opposite, antican-
cer activity of HO-1 was described, for example, in the 
case of breast or prostate cancer. Thus, although HO-1 
might be considered as a therapeutic target, it has to be 
taken into account that inhibition of HO-1 not in every 
cancer cell type will be desired. Even more complicated 
is the fact that contradictory results were obtained within 
the same type of cancer, which might be at least partially 
related to different experimental settings. Especially in 
the case of metalloporphyrins, caution has to be taken 
in the interpretation of obtained results, since they might 
not be directly related to the activity of HO-1. Moreo-
ver, when considering the shRNA approach, off-target 
effects may result in the misinterpretation of observed 
results (Loboda et al., 2015). Thus, we do believe that 
CRISPR/Cas9 technology may represent the most reli-
able tool to study specific gene function. Moreover, to 
our best knowledge, depletion of HO-1 by CRISPR/
Cas9 technology has not been studied so far, and here 
we report that it can provide an alternative method to 
study biological effect of HO-1 inhibition in many areas 
of research, including tumour biology, which is now ex-
tensively studied by our group.
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